What question did this study set out to answer?

This work aims to review the evidence supporting brentuximab vedotin (BV) for cutaneous T-cell lymphoma (CTCL), particularly in CD30-negative and CD30-low cases.

June 15, 2026Cancer Treatment and Research CommunicationsOpen Access

Brentuximab vedotin in cutaneous T-Cell lymphoma: emerging evidence and therapeutic insights for CD30-negative and CD30-low disease

View Full Paper

Ask AI

Bookmark

Authors

RMRenée MorecroftWashington University in St. Louis JPJordan PhillippsWinnMed MMMuhamad Alhaj MoustafaJacksonville College

Discussion

Member takes

Implication

Review highlights emerging evidence on brentuximab vedotin for treating CD30-negative cutaneous T-cell lymphoma, suggesting potential efficacy.

Key Points

This work aims to review the evidence supporting brentuximab vedotin (BV) for cutaneous T-cell lymphoma (CTCL), particularly in CD30-negative and CD30-low cases.
Performed a comprehensive literature review of prospective trials, retrospective analyses, and real-world studies.
Examined BV's mechanism, predictors of response, safety, and guideline recommendations for varying CD30 levels.
Focused on the efficacy of BV in CD30-negative and CD30-low CTCL patients.
BV shows superior efficacy in CD30-positive CTCL with higher response rates and progression-free survival versus standard therapies, as seen in the ALCANZA trial.
Limited and inconsistent responses were observed in clinical trials for CD30-negative patients, highlighting challenges in this subgroup.
Real-world data suggest potential meaningful responses in CD30-negative and CD30-low diseases, possibly owing to low-level CD30 expression or bystander cytotoxicity.

Cite This Study

Morecroft et al. (2026) studied this question.

synapsesocial.com/papers/6a2f96eca1cfeec49082807f https://doi.org/10.1016/j.ctarc.2026.101277

View Full Paper

Ask AI

Bookmark

Implication

Review highlights emerging evidence on brentuximab vedotin for treating CD30-negative cutaneous T-cell lymphoma, suggesting potential efficacy.

Brentuximab vedotin in cutaneous T-Cell lymphoma: emerging evidence and therapeutic insights for CD30-negative and CD30-low disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Brentuximab vedotin in cutaneous T-Cell lymphoma: emerging evidence and therapeutic insights for CD30-negative and CD30-low disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider